ArticleMolecular plant pathology2025
GmMEKK2 Disrupts the MKK1/2-MPK4 Cascade to Amplify Immune Signalling and Confer Enhanced Resistance to Soybean Mosaic Virus.
Article in Molecular plant pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Decoding MAPK cascades in plant immunity: Activation, regulation, integration, and pathogen manipulation.Journal of integrative plant biology · 2026Review
- GmMEKK2 Disrupts the MKK1/2-MPK4 Cascade to Amplify Immune Signalling and Confer Enhanced Resistance to Soybean Mosaic Virus.Molecular plant pathology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Mitogen-activated protein kinase kinase kinase (MAPKKK) assumes a pivotal position within the MAPK cascade, converting external stimuli into intracellular responses and mediating plant stress resistance. However, there are limited reports investigating its function in regulating resistance to soybean mosaic virus (SMV). Here, a MAPKKK2-like gene GmMEKK2 (LOC100798607) was identified from an SMV-resistant cultivar, with an amino acid sequence containing the typical conserved G(T/S)Px(W/Y/F)MAPExV domain, showing homology to AtMEKK1, AtMEKK2 (SUMM1) and OsMAPKKK5. Overexpression of GmMEKK2 in soybean reduced SMV accumulation and the disease index, mitigated the yield loss after SMV inoculation and improved yield traits. In contrast, silencing GmMEKK2 via virus-induced gene silencing (VIGS) significantly enhanced SMV susceptibility, with increased disease index and viral content. Transcriptionally, defence responce genes such as PR1s and RPM1s were pre-activated in the overexpression lines before SMV infection, conferring soybean with preventive resistance. While non-transgenic plants showed severe down-regulation of basic metabolic genes and strong induction of genomic repair genes at 14 days post-inoculation (dpi), overexpression lines exhibited minimal changes. Despite lacking kinase activity, GmMEKK2 bound with GmMKK1 and GmMPK4A to block the MKK1/2-MPK4 cascade, thereby indirectly enhancing the salicylic acid-induced defence responses. Additionally, GmMEKK2 overexpression elevated basal reactive oxygen species (ROS) levels to trigger autoimmunity, while maintaining ROS homeostasis via the antioxidant enzyme system in soybean. This study clarifies the function and molecular mechanism of GmMEKK2 in SMV resistance, providing a strategy for improving soybean SMV resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.